# CRMD catalysts: CorMedix Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/crmd/catalysts

> CorMedix Inc. (CRMD) has 4 upcoming catalysts. The next is the REZZAYO® (rezafungin) PDUFA date, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CRMD?

CorMedix Inc. (CRMD) has 4 upcoming catalysts. The next is the REZZAYO® (rezafungin) PDUFA date, Q1 2027. Press release filed with the SEC (EX-99): "The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027." [Calendar and source filings](https://sec-api.dev/companies/crmd/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-110477, https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/crmd/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CorMedix Inc. |
| Ticker | CRMD (Nasdaq) |
| SEC CIK | 1410098 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/crmd |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 26, 2021 | [Defencath (heparin sodium; taurolidine) complete response letter (CRL)](https://sec-api.dev/pdufa/heparin-taurolidine) | CRMD |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214520_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| August 4, 2022 | [Defencath (heparin sodium; taurolidine) complete response letter (CRL)](https://sec-api.dev/pdufa/heparin-taurolidine) | CRMD |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214520_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| November 15, 2023 | [DefenCath (defencath) FDA approval](https://sec-api.dev/pdufa/defencath) | CRMD | kidney failure receiving chronic hemodialysis | completed, approved | "The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm)) |
| November 15, 2023 | [Defencath (heparin sodium; taurolidine) FDA approval](https://sec-api.dev/pdufa/heparin-taurolidine) | CRMD |  | completed, approved | "Defencath \| taurolidine, heparin \| 11/15/2023 \| To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheterDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| January 7, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary Fourth quarter 2024 results and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea022695701ex99-1_cormedix.htm)) |
| March 25, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "INC. REPORTS fourth QUARTER and full year 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520ex99-1_cormedix.htm)) |
| April 8, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701ex99-1_cormedix.htm)) |
| May 6, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea024082701ex99-1_cormedix.htm)) |
| August 6, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm)) |
| September 15, 2025 | [L-3721 FDA approval](https://sec-api.dev/pdufa/l-3721) | CRMD |  | completed, approved | "a.The creation of the role of Chief Manufacturing Officer on September 15, 2025, which role, among other things, (i) is held by someone with experience developing pharmaceutical products that received FDA approval, (ii) has primary responsibility for managing the Company's pharmaceutical development and testing procedures and policies and assisting the Board with its oversight duties regarding the Company's development; and (iii) will create, implement, and maintain a policy of generally accepted testing principles and standards." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-8xkxaugust72026xex992.htm)) |
| October 20, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary THIRD quarter 2025 results and RAISES 2025 NET REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea026176001ex99-1_cormedix.htm)) |
| November 12, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports third Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025108716/ea026513601ex99-1_cormedix.htm)) |
| January 5, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CorMedix announces preliminary, unaudited financial results for Q4 and FY 2025, including net revenue of approximately $127 million and $310 million, for Q4 2025 and FY 2025, respectively, FY 2025 Pro Forma net revenue(1) of approximately $400 million, and Q4 2025 adjusted EBITDA(2) in the range of $77 million to $81 million." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea027214901ex99-1_cormedix.htm)) |
| March 5, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports FOURTH Quarter AND FULL YEAR 2025 Financial Results and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001ex99-1.htm)) |
| Q2 2026 | [CorMedix Inc. topline data readout](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | scheduled | "This Phase III study, which is being conducted by our licensor Mundipharma, completed enrollment in September 2025, and we expect to announce top-line data in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm)) |
| April 27, 2026 | [REZZAYO® (rezafungin) topline data readout](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | completed, positive | "•On April 27, 2026, CorMedix announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd_q12026earningspr.htm)) |
| May 14, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd_q12026earningspr.htm)) |
| 2H 2026 | [REZZAYO® (rezafungin) NDA/BLA submission](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | scheduled | "The companies anticipate a pre-NDA submission meeting with FDA in the coming months, followed by a target submission of a supplemental New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea028764001ex99-1.htm)) |
| August 13, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd_q22026earningspr.htm)) |
| October 19, 2026 | [REZZAYO® (rezafungin) NDA/BLA acceptance](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | completed | "NJ - October 19, 2026 - CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm)) |
| November 12, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "CORMEDIX THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000063/crmd_q32026earningspr.htm)) |
| Q1 2027 | [REZZAYO® (rezafungin) PDUFA date](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | scheduled | "The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm)) |
| 2H 2027 | [REZZAYO® (rezafungin) PDUFA date](https://sec-api.dev/pdufa/rezafungin) | CRMD |  | scheduled | "We look forward to working closely with Mundipharma in the coming months ahead of FDA's action date and will begin to prepare for a potential promotional launch in the second half of 2027."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea030895701ex99-1.htm)) |
| January 2028 | [(taurolidine and heparin) catheter lock solution primary completion](https://sec-api.dev/pdufa/taurolidine-and-heparin-catheter-lock-solution) | CRMD | Central Line Associated Blood Stream Infections (CLABSI) | scheduled | "NCT06822426 (Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor CorMedix Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822426)) |
| Jan to Apr 2028 | [(taurolidine and heparin) catheter lock solution topline data readout](https://sec-api.dev/pdufa/taurolidine-and-heparin-catheter-lock-solution) | CRMD | Central Line Associated Blood Stream Infections (CLABSI) | scheduled | "NCT06822426 (Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor CorMedix Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822426)) |

## Drugs

- [DefenCath (defencath)](https://sec-api.dev/pdufa/defencath): kidney failure receiving chronic hemodialysis
- [Defencath (heparin sodium; taurolidine)](https://sec-api.dev/pdufa/heparin-taurolidine): 
- [L-3721](https://sec-api.dev/pdufa/l-3721): 
- [REZZAYO® (rezafungin)](https://sec-api.dev/pdufa/rezafungin): 
- [(taurolidine and heparin) catheter lock solution](https://sec-api.dev/pdufa/taurolidine-and-heparin-catheter-lock-solution): Central Line Associated Blood Stream Infections (CLABSI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/crmd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRMD catalysts: CorMedix Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/crmd/catalysts

```bibtex
@misc{secapidev_companies_crmd_catalysts_20261116,
  title        = {CRMD catalysts: CorMedix Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/crmd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_crmd_catalysts_20261116","title":"CRMD catalysts: CorMedix Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/crmd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
